| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CD327; CD33L; OBBP1; CD33L1; CD33L2; CDW327 |
| WB Predicted band size | 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SIGLEC6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于 **SIGLEC6抗体** 的参考文献(内容基于假设性研究整理，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*SIGLEC6 as a potential therapeutic target in placental disorders*
**作者**：Patel, N. et al.
**摘要**：研究探讨了SIGLEC6在胎盘组织中的特异性表达及其与妊娠疾病的关联，开发了针对SIGLEC6的单克隆抗体，验证了其在抑制异常胎盘细胞增殖中的作用。
2. **文献名称**：*Siglec-6 mediates immunosuppression in B-cell malignancies*
**作者**：Angata, T. et al.
**摘要**：通过抗SIGLEC6抗体阻断实验，揭示了SIGLEC6在B细胞淋巴瘤微环境中的免疫抑制功能，表明其抗体可能增强抗肿瘤免疫反应。
3. **文献名称**：*Antibody-based targeting of SIGLEC6 in chronic lymphocytic leukemia*
**作者**：Hudak, J.E. et al.
**摘要**：研究利用人源化抗SIGLEC6抗体在慢性淋巴细胞白血病(CLL)模型中展示疗效，证明其可诱导癌细胞凋亡并抑制肿瘤生长。
4. **文献名称**：*Structural characterization of SIGLEC6 and its antibody interaction*
**作者**：Kreitman, R.J. & Pastan, I.
**摘要**：通过X射线晶体学解析了SIGLEC6蛋白结构，并分析了抗体结合表位，为开发高特异性诊断/治疗抗体提供了分子基础。
---
建议通过 **PubMed** 或 **Web of Science** 输入关键词“SIGLEC6 antibody”或“anti-SIGLEC6”获取真实文献数据。
SIGLEC6 (sialic acid-binding immunoglobulin-type lectin 6) is a transmembrane protein belonging to the SIGLEC family of immune-regulatory receptors. It is primarily expressed in placental trophoblasts, B cells, and basophils, where it interacts with sialylated glycans on cell surfaces. Structurally, it contains an N-terminal V-set immunoglobulin domain that mediates ligand binding, followed by multiple C2-set domains and cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that transmit inhibitory signals upon activation.
Functionally, SIGLEC6 acts as a inhibitory receptor, dampening immune responses by recruiting phosphatases like SHP-1/SHP-2. Its ligand specificity includes binding to sialylated glycoproteins such as CD163L1 and pregnancy-specific glycoproteins (PSGs), suggesting roles in placental development and immune tolerance during pregnancy. Dysregulation of SIGLEC6 has been implicated in pathological conditions, including chronic lymphocytic leukemia (CLL) and gestational trophoblastic diseases, where it may serve as a diagnostic or therapeutic target.
Antibodies targeting SIGLEC6 are valuable tools for studying its expression patterns, ligand interactions, and signaling mechanisms. Therapeutic applications are being explored, particularly in cancers with SIGLEC6 overexpression, through antibody-drug conjugates or checkpoint blockade strategies. Research continues to elucidate its precise physiological roles and clinical potential.
×
